David A. Siegel Nuvation Bio Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 454,900 shares of NUVB stock, worth $1.65 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
454,900
Previous 358,800
26.78%
Holding current value
$1.65 Million
Previous $631,000
40.57%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding NUVB
# of Institutions
195Shares Held
168MCall Options Held
2.31MPut Options Held
221K-
Decheng Capital LLC Menlo Park, CA26MShares$94.2 Million12.78% of portfolio
-
Black Rock Inc. New York, NY16.2MShares$58.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.9MShares$57.7 Million0.0% of portfolio
-
Omega Fund Management, LLC Boston, MA11MShares$40.1 Million46.36% of portfolio
-
Laurion Capital Management LP New York, NY10.2MShares$37.2 Million0.37% of portfolio
About Nuvation Bio Inc.
- Ticker NUVB
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 217,244,000
- Market Cap $789M
- Description
- Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...